Programs
Clinical & Commercial Programs
AIVITA’s lead therapeutic focus is a patient-specific immunotherapy for the treatment of advanced cancers, currently being investigated in glioblastoma and melanoma. We are also developing a personalized vaccine for the prevention of COVID-19.
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- Commercialization
Tumor-initiating cell vaccine (Glioblastoma)
Tumor-initiating cell vaccine (Melanoma)
Tumor-initiating cell vaccine + checkpoint inhibitor (Melanoma)
Tumor-initiating cell vaccine + checkpoint inhibitor (Melanoma)
Vaccine Enabling Kit (COVID-19)